Literature DB >> 10512740

Pharmacological and signaling analysis of human chemokine receptor CCR-7 stably expressed in HEK-293 cells: high-affinity binding of recombinant ligands MIP-3beta and SLC stimulates multiple signaling cascades.

S K Sullivan1, D A McGrath, D Grigoriadis, K B Bacon.   

Abstract

The chemokine receptor CCR-7 is expressed in T, NK, and dendritic cells in a time-ordered and stimulus-dependent manner. Thorough analyses of the pharmacological profiles of the recombinant ligands for CCR-7, MIP-3beta/ELC/CK-beta 11, and SLC/Exodus-2/TCA4/6C-kine, using CCR-7-expressing HEK-293E transfectants determine that ligands both bind with a K(d) in the 100 pM range-10- to 100-fold greater affinities than published K(d) values. High-affinity binding of each ligand is associated with rapid mobilization of intracellular calcium and cell migration as predicted for chemokine GPCRs, and in keeping with more recent evidence, robust activation of mitogen-activated protein kinase (MAPK). Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10512740     DOI: 10.1006/bbrc.1999.1442

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  Regulation of hematopoiesis by chemokine family members.

Authors:  H E Broxmeyer
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

2.  CCR7 deficiency leads to leukocyte activation and increased clearance in response to pulmonary Pseudomonas aeruginosa infection.

Authors:  Bryan L Eppert; Gregory T Motz; Brian W Wortham; Jennifer L Flury; Michael T Borchers
Journal:  Infect Immun       Date:  2010-02-22       Impact factor: 3.441

3.  Arrestin 3 mediates endocytosis of CCR7 following ligation of CCL19 but not CCL21.

Authors:  Melissa A Byers; Psachal A Calloway; Laurie Shannon; Heather D Cunningham; Sarah Smith; Fang Li; Brian C Fassold; Charlotte M Vines
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

4.  Dendritic cell chemotaxis in 3D under defined chemokine gradients reveals differential response to ligands CCL21 and CCL19.

Authors:  Ulrike Haessler; Marco Pisano; Mingming Wu; Melody A Swartz
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

Review 5.  Diversity in arrestin function.

Authors:  Ryan T Kendall; Louis M Luttrell
Journal:  Cell Mol Life Sci       Date:  2009-07-12       Impact factor: 9.261

6.  Lymphoidal chemokine CCL19 promoted the heterogeneity of the breast tumor cell motility within a 3D microenvironment revealed by a Lévy distribution analysis.

Authors:  Beum Jun Kim; Pimkhuan Hannanta-Anan; Anders Ryd; Melody A Swartz; Mingming Wu
Journal:  Integr Biol (Camb)       Date:  2020-02-22       Impact factor: 2.192

7.  Expression of the C-C chemokine receptor 7 mediates metastasis of breast cancer to the lymph nodes in mice.

Authors:  Heather D Cunningham; Laura A Shannon; Psachal A Calloway; Brian C Fassold; Irene Dunwiddie; George Vielhauer; Ming Zhang; Charlotte M Vines
Journal:  Transl Oncol       Date:  2010-12-01       Impact factor: 4.243

8.  Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands.

Authors:  David A Zidar; Jonathan D Violin; Erin J Whalen; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-02       Impact factor: 11.205

9.  The dependence of chemokine-glycosaminoglycan interactions on chemokine oligomerization.

Authors:  Douglas P Dyer; Catherina L Salanga; Brian F Volkman; Tetsuya Kawamura; Tracy M Handel
Journal:  Glycobiology       Date:  2015-11-17       Impact factor: 4.313

10.  Fusion of CCL21 non-migratory active breast epithelial and breast cancer cells give rise to CCL21 migratory active tumor hybrid cell lines.

Authors:  Benjamin Berndt; Sonja Haverkampf; Georg Reith; Silvia Keil; Bernd Niggemann; Kurt S Zänker; Thomas Dittmar
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.